154 results on '"Fonder, Amie L."'
Search Results
2. Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
3. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy
4. First relapse in patients with multiple myeloma: Outcomes and predictors.
5. Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update
6. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes
7. A simple additive staging system for newly diagnosed multiple myeloma
8. Impact of acquired del(17p) in multiple myeloma
9. Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis
10. Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma
11. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma
12. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma
13. Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis
14. Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse
15. Delineation of the timing of second-line therapy post–autologous stem cell transplant in patients with AL amyloidosis
16. The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?
17. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance
18. Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis
19. Natural history of multiple myeloma with de novo del(17p)
20. Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival
21. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
22. Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma
23. Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL)
24. Efficacy of daratumumab‐based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials
25. Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation
26. Prognostic significance of acquired 1q22 gain in multiple myeloma
27. Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort
28. Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide
29. Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia
30. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes
31. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice
32. Prognostic significance of acquired 1q22 gain in multiple myeloma.
33. Addition of venetoclax at time of progression in ibrutinib‐treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare
34. Atrial fibrillation (AF) in patients with CLL treated with ibrutinib: Assessing prediction models and clinical outcomes.
35. Clinical and cytogenetic features of nonsecretory multiple myeloma (NSMM) in the era of novel agent induction therapy: The Mayo Clinic experience.
36. Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy
37. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice
38. Addition of venetoclax at time of progression in ibrutinib‐treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.
39. Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse
40. Utility and prognostic value of18F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma
41. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement
42. Rapid progression of disease following ibrutinib discontinuation in patients with chronic lymphocytic leukemia.
43. Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.
44. Duration of complete response (DurCR) impacts overall survival (OS) in multiple myeloma (MM).
45. Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis
46. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma
47. Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL)
48. Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis
49. Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia
50. What are patients’ biggest concerns? A patient reported outcome case-management system.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.